TE1 Stock Overview
Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bio-Techne Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$57.00 |
| 52 Week High | US$78.50 |
| 52 Week Low | US$53.50 |
| Beta | 1.29 |
| 1 Month Change | -8.80% |
| 3 Month Change | -20.28% |
| 1 Year Change | -14.29% |
| 3 Year Change | -40.31% |
| 5 Year Change | 42.50% |
| Change since IPO | 398.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| TE1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -3.4% | 0.6% | 0.5% |
| 1Y | -14.3% | -15.2% | 15.4% |
Return vs Industry: TE1 exceeded the German Life Sciences industry which returned -15.8% over the past year.
Return vs Market: TE1 underperformed the German Market which returned 15.5% over the past year.
Price Volatility
| TE1 volatility | |
|---|---|
| TE1 Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: TE1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: TE1's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 3,100 | Kim Kelderman | www.bio-techne.com |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Bio-Techne Corporation Fundamentals Summary
| TE1 fundamental statistics | |
|---|---|
| Market cap | €9.03b |
| Earnings (TTM) | €145.28m |
| Revenue (TTM) | €1.10b |
62.2x
P/E Ratio8.2x
P/S RatioIs TE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TE1 income statement (TTM) | |
|---|---|
| Revenue | US$1.20b |
| Cost of Revenue | US$404.01m |
| Gross Profit | US$792.00m |
| Other Expenses | US$633.90m |
| Earnings | US$158.10m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 66.22% |
| Net Profit Margin | 13.22% |
| Debt/Equity Ratio | 14.4% |
How did TE1 perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield32%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 08:32 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Techne Corporation is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| James Francis Mainwaring | Atlantic Equities LLP |
| Catherine Ramsey Schulte | Baird |